{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T01:55:17Z","timestamp":1781056517508,"version":"3.54.1"},"reference-count":0,"publisher":"Oceanside Publications Inc.","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2020,5,1]]},"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> There is limited real-world evidence on hereditary angioedema (HAE) patient characteristics and health-care resource utilization (HCRU); in addition, pediatric patients have been described in small cohorts.  <jats:bold>Objective:<\/jats:bold> To describe patient characteristics,\n treatment patterns, and HCRU among adult and pediatric patients treated for HAE in a large U.S. cohort.  <jats:bold>Methods:<\/jats:bold> This retrospective cohort study used an administrative claims data base (January 2006 to September 2015). Eligible patients with either \u22651 pharmacy claim\n for HAE-indicated therapies (C1 inhibitors, ecallantide, icatibant) or \u22652 medical claims with codes associated with HAE (per medical billing codes), and \u22651 claim for androgens, fresh frozen plasma, tranexamic acid, or \u03b5-aminocaproic acid formed a \u201ctreated cohort.\u201d Three\n nonexclusive treated cohorts were assessed: overall, pediatric, and HCRU (\u22652 years of continuous enrollment during 2010\u20102015).  <jats:bold>Results:<\/jats:bold> Overall, 1429 patients received treatment (mean \u00b1 standard deviation [SD] age, 38.8 \u00b115.7 years; 62.4% female\n patients; mean \u00b1 SD Charlson Comorbidity Index of 1.4 \u00b1 2.4). Common comorbidities were allergy or anaphylaxis (51.4%) and anxiety or depression (35.8%). Diagnoses indicative of HAE attacks included swelling and\/or angioedema (78.5%), abdominal pain (55.6%), and asphyxiation\n (27.2%). Use of HAE-indicated medication rose between 2006 and 2015 to 81.8%, whereas androgen use declined (from 91.5% to 24.9%). Similar trends were observed in the pediatric treated cohort (n = 143). In the HCRU treated cohort (n = 538), HAE-related claims for emergency department and inpatient\n admissions were observed for 36.6% and 22.3% of patients, respectively.  <jats:bold>Conclusion:<\/jats:bold> In a large U.S. cohort of adult and pediatric patients who received treatments indicated or used for HAE, common comorbidities and trends in resource use denoted the substantial burden of\n attacks, which reflected a continued need that recently approved long-term prophylactic treatments may help to address.<\/jats:p>","DOI":"10.2500\/aap.2020.41.200011","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T04:38:52Z","timestamp":1588826332000},"page":"172-182","source":"Crossref","is-referenced-by-count":14,"title":["Real-world cohort study of adult and pediatric patients treated for hereditary angioedema in the United States"],"prefix":"10.2500","volume":"41","author":[{"given":"Raffi","family":"Tachdjian","sequence":"first","affiliation":[{"name":"From the AIRE Medical of Los Angeles, and Division of Allergy & Clinical Immunology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin E.","family":"Johnson","sequence":"additional","affiliation":[{"name":"IQVIA, Epidemiology and Drug Safety Practice, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Casso","sequence":"additional","affiliation":[{"name":"IQVIA, Epidemiology and Drug Safety Practice, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan A.","family":"Oliveria","sequence":"additional","affiliation":[{"name":"IQVIA, Epidemiology and Drug Safety Practice, New York, New York, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Devercelli","sequence":"additional","affiliation":[{"name":"Shire, a Takeda company, Division of Global Evidence and Outcomes, Lexington, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gagan","family":"Jain","sequence":"additional","affiliation":[{"name":"Shire, a Takeda company, Division of Global Evidence and Outcomes, Lexington, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1355","container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2020\/00000041\/00000003\/art00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T04:42:32Z","timestamp":1590554552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2020.41.200011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,1]]},"references-count":0,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,5,1]]}},"alternative-id":["1088-5412(20200501)41:3L.172;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2020.41.200011","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5,1]]}}}